Straits Times Index
3,220.98 +47.05 (+1.48%) S&P 500
3,936.97 -65.90 (-1.65%) Dow
32,030.11 -530.49 (-1.63%) Nasdaq
11,669.96 -190.15 (-1.60%) Bitcoin USD
26,978.50 -1,132.91 (-4.03%) CMC Crypto 200
588.20 -27.74 (-4.50%)
GILD Jun 2023 75.000 put
- Zacks
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.
- Business Wire
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
FOSTER CITY, Calif., March 22, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother’s Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative. These grants are part of Gilead’s ongoing Zeroing In™ program
- Zacks
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
